Compass Pathways to Participate in December Investor Conferences

Rhea-AI Summary

Compass Pathways (Nasdaq: CMPS), a mental health biotechnology company, has announced its participation in two major investor conferences this December. The company's executive management team will engage in fireside chats at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, at 10:25am ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:30pm ET. Live audio webcasts will be available for 30 days after the events.

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings:

• 7^th Annual Evercore ISI HealthCONx Conference: Fireside chat at 10:25am ET on December 3, 2024
• Piper Sandler 36^th Annual Healthcare Conference: Fireside chat at 3:30pm ET on December 4, 2024

A live audio webcast of these events will be accessible here for 30 days following the events.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We have completed an open label phase 2 study of COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD), and we are currently conducting a phase 2 clinical study in anorexia nervosa.

Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing.

Availability of other information about Compass Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241125241648/en/

Enquiries

Media: Sally Bain, sally.bain@compasspathways.com, + 1 781 458 0443

Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

Source: Compass Pathways plc

FAQ

When is Compass Pathways (CMPS) presenting at the Evercore ISI HealthCONx Conference 2024?

Compass Pathways will present at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, at 10:25am ET.

What investor conferences is Compass Pathways (CMPS) attending in December 2024?

Compass Pathways is attending two conferences: the 7th Annual Evercore ISI HealthCONx Conference on December 3 and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024.

How long will the Compass Pathways (CMPS) December 2024 conference webcasts be available?

The live audio webcasts will be accessible for 30 days following the events.

What time is Compass Pathways (CMPS) presenting at the Piper Sandler Healthcare Conference 2024?

Compass Pathways will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:30pm ET.